ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Thursday, July 15, 2010

National MS Society Works with Reps. Kilroy & Thornberry to Introduce & Confirm Legislation to Cover Off-Label Prescriptions for Medicare Part D Carriers

July 14, 2010



H.R. 5732, the “Part D Off-Label Prescription Parity Act" was confirmed in Congress Wednesday.  The bill is desgined to allow Medicare coverage of off-label medication when its use is supported by peer-reviewed medical literature, as is the case for Medicare Part B and for Part D medications used to treat cancer. With key consultation and support from noted clinicians and other health organizations, the Society has worked closely with Reps. Kilroy and Thornberry to draft this legislation. Linda Buchwald M.D. and Chief of Neurology and Medical Director of the MS Comprehensive Care Center in Cambridge, MA and Randy Shapiro President of the Schapiro Multiple Sclerosis Advisory Group in Eagle, CO, the Medicare Rights Center and the National Organization for Rare Disorders were instrumental in the development and championing of this bills’ introduction. 
Currently, many Medicare consumers who suffer from chronic conditions, such as MS, are unable to access safe and effective medications under Part D, which does not allow coverage for drugs that are used off-label.  The cost of MS disease-modifying therapies and symptom treatments can be staggering and not always covered by insurance. Access to prescribed drugs, however, can often allow people with MS to live active and productive lives. Doctors, based on existing medical literature and their professional judgment, routinely prescribe medications for off-label uses, meaning the drugs are used for purposes other than those originally approved by the Food and Drug Administration (FDA).  “Doctors and patients should be able to decide the best safe and effective medications for their treatments,” said Rep. Kilroy. “We must fight for the right to be treated with the best, safest medicine in consultation with our physicians, not a government bureaucrat.”

Continue reading from here

*
*
***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

0 comments: